Sitemap
Pages
- Sitemap
- Get Instant Quote
- ThankYou
- About us new
- Who we serve
- Resources
- Home
- Privacy Policy
- Term Of Use
- Policy Statement
- Who we are
Posts by category
- Category: Uncategorized
Events
- Antibody Engineering & Therapeutics
- LASACON 2025
- CPHI Pmec India 2025
- AFDD (Antifibriotic Drug Development Summit) (Hansonwade) 2025
- PEGS Europe 2025
- Bio-Manufacturing World Summit 2025
- CPHI Worldwide 2025
- Fierce Biotech Week
- ISPE Product Show (Boston Chapter)
- DCAT 2026
- Annual Conference of the Society for the Study of Xenobiotics
- Bio Asia 2026
- 10th Anniversary Tumor Models Summit
- Biologics 2026 - Emerging Frontiers (Biopharmaceutical Product Development)
- CHI's PepTalk 2026
- Biotech Showcase
- JP Morgan Healthcare Conference 2026
- Festival of Biologics 2025
- IPF Summit
- BIO International 2025
- PEGS BOSTON
- Festival of Biologics 2024
- 8th Annual IPF Summit
- The Bioprocessing Summit 2024
- DCAT
- CHI's PepTalk
- Antibody Engineering & Therapeutics
- Festival of Biologics
- BioProcess International (BPI East)
- The Bioprocessing Summit 2023
- Antibody Engineering & Therapeutics Europe 2023
- BIO International
- PEGS Boston Summit
- Generis American Biomanufacturing Summit
- PEGS Boston Summit
Leaders
- Subodh Deshmukh
- Malavika Ghosh, PhD
- Keshav Vasanthavada
- Sufia Karim, MD
- Divya Khaitan, PhD
- Elizabeth Stillman, PhD
- Robert Richard Ruffolo, PhD
- Dr. Bruce E. Schneider
- Dr. Emilio A. Emini
- Manni Kantipudi
- Elizabeth Garcia
- Sowjanya Kumar Reddy
News
- Aragen Launches CHOMax™, an Accelerated Platform for DNA to IND-Enabling Clinical Supply in ~10 Months
- Aragen Bioscience Validates Getinge’s Single-Use Production Reactor (SUPR)
- Aragen's Validation Journey with Getinge's SUPR Single-Use Bioreactors
- Aragen operationalizes first phase of its Biologics manufacturing facility in India
- Aragen setting up a $ 30 million bio-manufacturing site in India
- Analytical Prowess Powers Efficient CLD Through Data-Driven Decision-Making
- Forging robust partnerships in biologics development
- Aragen launches royalty-free CHO GS cell line development platform under RapTr2022
- Best practices & strategies for biotherapeutics production using a stable scale-up process
- Long-acting injectables for biologics: Current landscape and future perspective
- FAR Biotech and Aragen Life Sciences Enter into a Collaboration to Advance Preclinical Program in Neurodegeneration
Resources
- Accelerating Cell Line Development for Biologics and Biosimilars
- Integrated In vivo Oncology Studies for Predictive Preclinical Efficacy Outcomes
- On demand webinar - Advanced In Vivo Efficacy Models for Preclinical Success
- Transforming Biologics Manufacturing Through Smart Upstream Process Intensification
- Challenges and Solutions in Cell Line Development for Biologics
- Enhancing Biopharmaceutical Manufacturing with Single-Use Bioreactors: A Transformative Solution for CRDMO Operations
- Pharmacokinetic Assessment and Anti-Drug Antibodies Assessment of GLP-1 Receptor Agonists
- AI-Powered Digital Pathology for Pulmonary Fibrosis Biomarker Quantification
- Reliable and Reproducible Preclinical Rodent Models of MASH
- Phenotypic Characterization of Bleomycin-Induced Pulmonary Fibrosis Model in Mice
- Comparative Analysis: Responses to Immunotherapy
- Therapeutic Impact of an ALK5 Inhibitor Across Multiple Preclinical Fibrosis Models
- Your partner for timely, accurate and high-quality preclinical efficacy studies
- Selective ROCK2 inhibitor ameliorates established dermal and pulmonary fibrosis in murine systemic sclerosis and shifts the balance between Th17 and Treg cells in vivo
- Novel Technique for Quick and Easy Aggregate Removal of Monoclonal Antibodies Using Competitive Binding on CEX
- Enhancing mAb platform process using Membrane chromatography (Affnity/Protein-A, using Sartobind Rapid A) for FIH molecules with focus on Optimizing cost and Accelerating timelines
- Resin recycling studies
- A Pre-clinical Study for Diet-induced Obesity
- Unravelling Immunological Depths: Exploring Oxazolone-induced Delayed-Type Hypersensitivity Model
- Gene to GMP: First-in-human in 8 Months with Optimized Cost
- Propelling Glioblastoma Research: Aragen Bioscience’s Orthotopic Model Solutions
- Unlocking Insights: A Translational Mouse Model for Non-Genetic Heterotopic Ossification
- Getinge Single-use Bioreactor (SUPR) Fed-batch Production Runs
- Upstream Process Development for Better Yield and Product Quality
- Cell Line Development Solutions for Biologics CHO CLD Platforms
- Comprehensive Solutions for Animal Health Biologics
- Preclinical Oncology Capabilities
- Preclinical Evaluation of new Antifibrotics in IPF Rodent Models
- The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development
- Driving Better titers and Shorter Timelines with a Robust and Scalable CHO DG44 Platform
- Brain Metastases – Challenges of Developing Clinically Relevant Preclinical Models
- Accelerating Biologics Development to Medicines: Key Drivers of Success
- Expression, in vivo Maturation and Tag-less Purification of a Recombinant Protein
- DSS-induced IBD Mouse Model for preclinical drug screening
- RSV Challenge Model for anti-RSV therapy
- Oncology solutions: Accelerate your cancer therapeutics development
- Preclinical evaluation of Novel drug candidates against SLE in NZB/W F1 mouse models
- Bleomycin-Induced Scleroderma mouse model for preclinical testing of novel therapeutics
- An optimal upstream process development approach to increase the titers of the monoclonal antibodies (mAbs)
- Integrated Cell Line Development Solutions
- Developability and Analytics Solutions
- Protein Analytics Solutions
- Comprehensive Characterization of Biologics
- Protein science solutions: Industry leading upstream and downstream capabilities
- Cell Line Development : Research cell banks in 5 months
- Mitigating CMC issues through holistic approach to developability assessment
- Industry Leading Hybridoma Technique for Accelerated Antibody Discovery
- A Comparative Efficiency Analysis of Commercial Transfection Reagents in HEK 293 Cells
Solutions
- Biologics
- Cell Line Development
- CHOMax™
- Protein Expression & Purification
- Analytical Services
- Method Life Cycle Management
- Reference Standard Qualification
- Stability Studies & Forced Degradation
- Bioassay Method Development
- Product Characterization
- Physicochemical Properties
- Spectroscopy Techniques & MALS
- Liquid Chromatography Techniques
- Electrophoresis Techniques
- DSF & SLS
- Biological & Functional Testing
- Cell based assay
- ELISA Assay
- Binding Affinity and Kinetics by SPR
- Biophysical Characterization
- Glycan Profiling
- Molecular weight Determination
- Peptide Mapping
- Disulfide Linkage Confirmation
- Routine Analytical Testing
- Platform Services for Biologics Development
- Process Development & Characterization
- GMP Manufacturing Services
- Infrastructure
- Robust Quality Management System
- Antibody Discovery
- Molecular Biology
- Preclinical Efficacy Testing
- Fibrosis
- In Vitro and Ex Vivo Assays Supporting In Vivo Fibrosis Studies
- Linking Multiple Preclinical Fibrosis Models through Gene Expression
- Liver Fibrosis
- Intestinal Fibrosis
- Kidney Fibrosis
- Dermal Fibrosis (Scleroderma)
- Lung (Pulmonary) Fibrosis
- Oncology
- Immunology and In Vitro Pharmacology
- Infectious Diseases
- Respiratory Diseases
- Gastrointestinal Diseases
- Viral Infections
- Vaccine Development
- Respiratory Diseases
- Histology and Digital Pathology Services
- Histology Services
- Digital Pathology Services
Testimonials
- Elisabeth Gardiner, PhD, Chief Scientific Officer, Meditope Biosciences, Inc
- Immunotherapy Company
- Diagnostic Company
- Animal Health Company
- Immunotherapy Company
- Immuno Oncology Company
- Clinical Stage Biotech Company
- Biotech Company
- Diagnostic Company